Get the Stockscreener App
25.00
0.28%
-0.07
Olema Pharmaceuticals Inc stock is traded at $25.00, with a volume of 875.84K.
It is down -0.28% in the last 24 hours and down -11.72% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$25.07
Open:
$25.06
24h Volume:
875.84K
Relative Volume:
0.24
Market Cap:
$2.00B
Revenue:
-
Net Income/Loss:
$-96.66M
P/E Ratio:
-11.63
EPS:
-2.15
Net Cash Flow:
$-83.73M
1W Performance:
-8.93%
1M Performance:
-11.72%
6M Performance:
+486.85%
1Y Performance:
+328.82%
1-Day Range:
$24.87
$25.76
1-Week Range:
$24.87
$27.66
52-Week Range:
$2.86
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
25.00 | 2.01B | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-12-25 | Reiterated | Citigroup | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
Insider Selling: Olema Pharmaceuticals (NASDAQ:OLMA) Director Sells 2,881 Shares of Stock - MarketBeat
Olema Pharmaceuticals director Harmon sells $82,194 in stock - Investing.com India
Olema Pharmaceuticals (OLMA) Stock: Weekend Read Ahead on the Pullback, Insider Sales, and Wall Street Targets Before Monday’s Open - ts2.tech
Olema Pharmaceuticals (OLMA) Stock Update: Weekend Snapshot, Insider Sales, Analyst Targets, and Key Catalysts Ahead of Monday - ts2.tech
Will Olema Pharmaceuticals’ (OLMA) Index Debut Quietly Redefine Its Standing Among Biotech Investors? - simplywall.st
Olema: 'Strong Buy' Maintained On OPERA-02 Trial Initiation & Additional Shots On Goal - Seeking Alpha
Olema Pharmaceuticals Insider Sold Shares Worth $1,553,544, According to a Recent SEC Filing - marketscreener.com
Olema Pharmaceuticals Insider Sold Shares Worth $7,873,109, According to a Recent SEC Filing - marketscreener.com
Olema Pharmaceuticals Insider Sold Shares Worth $7,530,148, According to a Recent SEC Filing - marketscreener.com
Olema pharma chief medical officer sells shares for $7.5m By Investing.com - Investing.com South Africa
Olema Pharmaceuticals (NASDAQ:OLMA) Insider Naseem Zojwalla Sells 70,000 Shares of Stock - MarketBeat
Insider Selling: Olema Pharmaceuticals (NASDAQ:OLMA) Insider Sells $2,752,418.94 in Stock - MarketBeat
David Myles Sells 51,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock - MarketBeat
Olema Pharmaceuticals ch. discov. Myles C. sells $1.55m in stock - Investing.com Australia
Olema Pharmaceuticals ch. discov. Myles C. sells $1.55m in stock By Investing.com - Investing.com South Africa
Olema pharma director Clark sells $7.87 million in shares - Investing.com India
Olema pharma director Clark sells $7.87 million in shares By Investing.com - Investing.com UK
Olema pharma chief medical officer sells shares for $7.5m - Investing.com
Olema Pharmaceuticals (OLMA): Reassessing Valuation After S&P Biotechnology Select Industry Index Inclusion - Sahm
Roche boosts Olema as breast cancer therapy succeeds in late-stage trial - MSN
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to S&P Biotechnology Select Industry Index - marketscreener.com
Olema Pharmaceuticals (OLMA) price target increased by 25.00% to 46.54 - MSN
How Olema Pharmaceuticals Inc. stock performs during Fed tightening cycles2025 AllTime Highs & Short-Term Trading Opportunity Alerts - Улправда
Aug Rallies: Will Olema Pharmaceuticals Inc. stock pay special dividendsJuly 2025 Gainers & Precise Swing Trade Entry Alerts - Улправда
Why Olema Pharmaceuticals Inc. stock is favored by pension fundsJuly 2025 Closing Moves & Verified Momentum Stock Watchlist - Улправда
Why Olema Pharmaceuticals Inc. stock is popular among millennialsJuly 2025 Intraday Action & Stock Portfolio Risk Control - Улправда
Officer Myles Files To Sell 51,000 Of Olema Pharmaceuticals Inc [OLMA] - TradingView — Track All Markets
Olema Pharmaceuticals (NASDAQ: OLMA) Stock: Latest News, Analyst Forecasts, and What’s Driving the Volatility on December 19, 2025 - ts2.tech
Is Olema Pharmaceuticals Inc. stock positioned well for digital economyQuarterly Trade Report & Detailed Earnings Play Strategies - DonanımHaber
Will Olema Pharmaceuticals Inc. stock pay special dividendsJuly 2025 Big Picture & Daily Technical Stock Forecast Reports - Улправда
Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 3.5%Time to Sell? - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Olema Pharmaceuticals Inc Stock Analysis and ForecastMomentum Trading Signals & Fast Profit Trading Tips - earlytimes.in
Olema Pharmaceuticals (NASDAQ:OLMA) Hits New 12-Month HighTime to Buy? - MarketBeat
Olema Oncology’s Stock Surge: Analyze Now? - timothysykes.com
Olema Oncology (OLMA) Sees Positive Surge in Stock Price - GuruFocus
Olema Pharmaceuticals Stock Surges Amid Analyst Optimism - TipRanks
Research Analysts Offer Predictions for OLMA FY2025 Earnings - MarketBeat
Lifesci Capital Has Positive Outlook of OLMA FY2025 Earnings - MarketBeat
Birchview Capital LP Invests $571,000 in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Citigroup maintains Olema Pharmaceuticals (OLMA) buy recommendation - MSN
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Raised to $48.00 - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Raised to $60.00 - MarketBeat
OLMA Stock: Citigroup Raises Price Target to $60, Maintains Buy - GuruFocus
Olema Pharmaceuticals (OLMA): HC Wainwright & Co. Raises Price T - GuruFocus
Olema Oncology (OLMA) Price Target Raised by Citi Amid Positive Trial Data - GuruFocus
Olema Pharmaceuticals (OLMA): Reassessing Valuation After Roche’s Phase 3 SERD Success Boosts Palazestrant Expectations - Sahm
Oppenheimer Raises Price Target for Olema Pharmaceuticals (OLMA) to $48 | OLMA Stock News - GuruFocus
OLMA: Goldman Sachs Raises Price Target to $38 on Maintained Buy Rating | OLMA Stock News - GuruFocus
The Goldman Sachs Group Issues Positive Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Up 6% Following Analyst Upgrade - MarketBeat
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):